Aims To examine the effect of valsartan on kidney outcomes in patients with impaired
glucose tolerance (IGT). Methods In a double‐blind randomized trial, 9306 patients with IGT …

It is unknown whether the angiotensin receptor antagonist valsartan exerts a renoprotective
effect on patients with type 2 diabetes and diabetic nephropathy independent of its …

This study was designed to compare the short-term (1-y) tolerability and antiproteinuric
efficacy of enalapril and valsartan in patients with type 2 diabetes. Fortytwo patients with …

Background Diabetic nephropathy is the leading cause of end-stage renal disease.
Interruption of the renin–angiotensin system slows the progression of renal disease in …

Objective Renin–angiotensin system blockade is now standard in the management of the
patient with type 2 diabetes mellitus. We aimed to investigate whether high doses of …

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL
Study. Background Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II …

Objective: To evaluate the efficacy and safety of 80 or 160 mg/day valsartan in Chinese adult
patients with essential hypertension and albuminuria. Methods: A multicenter prospective …

OBJECTIVE—Asia is predicted to have the largest population of patients with diabetes who
are at high risk for renal disease. In the Reduction of Endpoints in NIDDM with the …

OBJECTIVE To determine whether early administration of losartan slows progression of
diabetic kidney disease over an extended period. RESEARCH DESIGN AND METHODS We …

Background. Blockade of the renin–angiotensin system is the primary target in the treatment
of diabetic kidney disease. Angiotensin II subtype 1 (AT1) receptor antagonists reduce …